|
Forecast
Period
|
2026-2030
|
|
Market
Size (2024)
|
USD
394.21 Million
|
|
Market
Size (2030)
|
USD
588.70 Million
|
|
CAGR
(2025-2030)
|
6.87%
|
|
Fastest
Growing Segment
|
Amoxicillin
& Potassium Clavulanate
|
|
Largest
Market
|
Asia
Pacific
|
Market Overview
Global Clavulanic Acid Series API Market was valued
at USD 394.21 Million in 2024 and is expected to reach USD 588.70 Million by
2030 with a CAGR of 6.87% during the forecast period. The global clavulanic acid series
API market is primarily driven by the increasing demand for combination
antibiotics. Clavulanic acid is used to enhance the effectiveness of
penicillin-based antibiotics by inhibiting beta-lactamase enzymes that bacteria
produce to resist antibiotics. The rise in bacterial resistance and the growing
need for broad-spectrum antibiotics are significant factors fueling market
growth. The expansion of healthcare access in emerging markets and the
increasing prevalence of infections such as pneumonia, urinary tract infections,
and respiratory infections further contribute to the demand for clavulanic
acid-based medicines. The ongoing research into new drug formulations and the
increasing use of combination drugs in both human and veterinary medicine are
expected to sustain the market's growth.
Key Market Drivers
Rising Antibiotic Resistance and Need for Effective
Treatments
Antibiotic resistance remains one of the most
pressing challenges facing global healthcare today. Bacteria have evolved
numerous mechanisms to resist antibiotics, rendering many traditional
treatments ineffective. This growing problem is particularly severe in
healthcare settings, where infections like pneumonia, bloodstream infections,
and urinary tract infections are becoming harder to treat due to resistant
strains. The rise of multi-drug-resistant (MDR) and extensively drug-resistant
(XDR) bacteria highlights the urgent need for effective solutions. Clavulanic
acid, when combined with beta-lactam antibiotics such as amoxicillin, becomes
an essential tool in the fight against these resistant pathogens. In January
2021, the central government revealed the names of the first three companies
eligible for financial support under the production-linked incentive (PLI)
scheme aimed at promoting domestic manufacturing of critical key starting
materials (KSMs), drug intermediates, and active pharmaceutical ingredients
(APIs). The companies include Aurobindo Pharma, based in Hyderabad, Kinvan Pvt
Ltd from Mumbai, and the public sector firm Karnataka Antibiotics and
Pharmaceuticals.
Clavulanic acid acts as a beta-lactamase inhibitor,
which prevents bacteria from producing beta-lactamase enzymes that would
normally break down and deactivate the antibiotic. This mechanism significantly
boosts the effectiveness of beta-lactam antibiotics against resistant strains,
making it a cornerstone in combating bacterial resistance. As resistance
continues to rise, both healthcare professionals and pharmaceutical companies
are focusing on the development of combination therapies that feature clavulanic
acid. This growing demand for combination antibiotics to combat resistance is
driving the global clavulanic acid API market. In fact, this challenge is also
prompting more governments and global health organizations to implement
antibiotic stewardship programs that emphasize the importance of using
clavulanic acid and similar drugs to curb the spread of resistant bacteria,
thereby accelerating the demand for this API.
Expanding Pharmaceutical Applications and
Combination Drugs
The increasing prevalence of combination
antibiotics has significantly contributed to the growth of the global
clavulanic acid series API market. Clavulanic acid is primarily used as a
co-administered compound with amoxicillin to form amoxicillin-clavulanate, a
widely prescribed broad-spectrum antibiotic. This combination allows for more
effective treatment of a variety of bacterial infections, including respiratory
infections, urinary tract infections, skin infections, and gastrointestinal
infections. In February 2025, Jubilant Biosys, a
subsidiary of Jubilant Pharmova, announced the expansion of its research and
development (R&D) capabilities through the acquisition of an 80% stake in
JASMIN, a newly formed company by the French pharmaceutical giant Pierre Fabre
SA, for an undisclosed amount. Pierre Fabre will retain the remaining 20%
equity. As part of the deal, Jubilant Biosys will also acquire Pierre Fabre's
R&D center in Saint-Julien-en-Genevois, France. This acquisition is aimed
at strengthening Jubilant’s presence in Europe and enhancing its expertise in
biologics and antibody-drug conjugates (ADCs), a rapidly growing segment of the
pharmaceutical industry.
The expansion of pharmaceutical applications for
clavulanic acid comes from its proven efficacy in treating both Gram-positive
and Gram-negative bacteria, especially those producing beta-lactamase. The
effectiveness of clavulanic acid-based antibiotics in treating complex
bacterial infections has made them the go-to choice for medical professionals.
As the world continues to face challenges like emerging infectious diseases,
pandemic threats, and antimicrobial resistance, the demand for combination therapies
that include clavulanic acid is increasing. The growing number of chronic
diseases, such as diabetes and heart disease, also leads to an increased risk
of infections in immunocompromised individuals, which further drives the
adoption of combination antibiotics. In addition, with the pharmaceutical
industry's focus on drug innovation, new formulations incorporating clavulanic
acid are emerging, addressing more specific bacterial strains, which expands
the scope of its use even further.
Growing Prevalence of Infectious Diseases
The rising prevalence of infectious diseases
worldwide has emerged as a significant driver of the global clavulanic acid
series API market. Infections caused by bacteria, such as pneumonia,
tuberculosis, gastroenteritis, sinusitis, and urinary tract infections, are on
the rise globally. Many of these infections are caused by antibiotic-resistant
bacteria, making treatment options limited and driving the demand for more
effective antibiotics, including those containing clavulanic acid. According
to UNICEF data, Pneumonia is the leading cause of death among children, responsible for
the loss of over 700,000 children under the age of 5 each year, equating to
around 2,000 deaths daily. This includes approximately 190,000 newborns. Nearly
all of these deaths are preventable. Globally, there are over 1,400 cases of
pneumonia per 100,000 children, or roughly 1 case for every 71 children
annually. The highest incidence rates are observed in South Asia, with 2,500
cases per 100,000 children, and in West and Central Africa, with 1,620 cases
per 100,000 children.
In developing regions, where healthcare
infrastructure is often underdeveloped and access to quality medications can be
limited, infectious diseases spread rapidly and are harder to control. Diseases
such as cholera, dysentery, and diarrheal diseases, which are prevalent in
areas with poor sanitation, further contribute to the growing demand for
effective antibiotics. In emerging markets, the expansion of healthcare
infrastructure, as well as increased public health awareness, has resulted in a
more widespread distribution of combination antibiotics. These developments in
regions like Asia, Africa, and South America are causing a significant uptick
in demand for clavulanic acid-based antibiotics, which are crucial in combating
bacterial infections that continue to spread in these areas. With infectious
diseases continuing to burden healthcare systems globally, clavulanic acid
series APIs are expected to remain essential in infection management, driving
the market growth.
Increased Healthcare Access in Emerging Markets
The expanding access to healthcare in emerging
markets has played a crucial role in driving the growth of the Global
Clavulanic Acid Series API Market. In many countries within Asia-Pacific,
Africa, and South America, improvements in healthcare infrastructure, access to
essential medicines, and rising healthcare spending are contributing to
increased demand for antibiotics, particularly those containing clavulanic
acid. With populations in these regions growing rapidly and with rising
urbanization, the prevalence of infections is also on the rise, prompting
greater need for treatments.
In particular, countries like India, China, and
Brazil have experienced significant increases in healthcare spending, which has
allowed them to provide better access to life-saving antibiotics. Governments
and global health organizations, such as the World Health Organization (WHO)
and GAVI, are working to improve access to essential medicines by providing
subsidies and implementing vaccination programs that address diseases
contributing to high infection rates. The affordability and availability of
combination antibiotics, including those with clavulanic acid, have become
vital in treating infections in underserved populations in these emerging
regions. As global health initiatives expand and national health systems
strengthen, the demand for these antibiotics is expected to continue growing.
Cost-Effectiveness of Clavulanic Acid-Based
Antibiotics
One of the key drivers of the Global Clavulanic
Acid Series API Market is the cost-effectiveness of amoxicillin-clavulanate and
other combination antibiotics. In both developed and developing nations, the
healthcare industry faces the challenge of providing affordable treatments to
populations with varying levels of income. Clavulanic acid, when combined with
amoxicillin, creates a highly effective antibiotic at a relatively low cost
compared to other treatments, making it an attractive option for healthcare
systems worldwide. According to study “Effect of Amoxicillin and
Clavulanate Potassium Combined with Bazhengsan on Pediatric Urinary Tract
Infection”, The aim of this study was to investigate the therapeutic effects of
amoxicillin and clavulanate potassium in combination with Bazhengsan for
pediatric urinary tract infections (UTIs). Methods: The data of 120 children
with UTIs, treated at Wuhan Xinzhou District People’s Hospital from February
2019 to February 2020, were retrospectively analyzed. The children were
randomly divided into two groups: the experimental group (EG) and the control
group (CG), based on the order of admission. Both groups received amoxicillin
and clavulanate potassium suspension twice daily, with the EG also receiving
one dose of Bazhengsan daily. The treatment duration for both groups was 10
days.
In developing nations, affordable medicines are
crucial for ensuring widespread access to effective treatments. International
organizations, such as the Global Fund and UNICEF, have partnered with
pharmaceutical companies to subsidize the cost of drugs that are in high
demand, including clavulanic acid-based antibiotics. This affordability has
expanded the reach of these antibiotics, particularly in low-income regions,
where infections are widespread and healthcare budgets are limited. The
cost-effectiveness of combination therapies containing clavulanic acid has been
a decisive factor in their adoption in public health initiatives and hospital
formularies globally.
Download Free Sample Report
Key Market Challenges
Rising Production Costs and Supply Chain Disruptions
The production of clavulanic acid is a complex
process that requires specialized fermentation and synthesis techniques. The
production of high-quality clavulanic acid APIs involves significant raw
material costs and capital investment in specialized equipment. Manufacturers
often face fluctuating prices for key raw materials such as fermentation
substrates and chemicals, which can result in increased production costs. These
cost pressures can affect the final pricing of clavulanic acid-based
antibiotics, especially in price-sensitive markets where affordability is a key
concern.
The global supply chain for pharmaceutical
ingredients can be subject to disruptions, whether from natural disasters,
geopolitical factors, or trade restrictions. The COVID-19 pandemic, for
example, highlighted the vulnerabilities in the global pharmaceutical supply
chain, as manufacturers faced difficulties sourcing raw materials, facing
shipping delays, and experiencing interruptions in production. Such disruptions
can lead to delays in API supply, reduced availability of key products, and
higher production costs, which could impede the growth of the clavulanic acid
market.
Counterfeit and Substandard Products
The issue of counterfeit and substandard
pharmaceuticals is a significant challenge in the Global Clavulanic Acid Series
API Market. The increasing demand for clavulanic acid-based antibiotics,
particularly in emerging markets, has led to a rise in the production and
distribution of counterfeit drugs. These substandard products often contain
inferior or incorrect amounts of the active ingredient, which can reduce the
effectiveness of treatment and contribute to the development of antimicrobial
resistance (AMR).
Counterfeit and substandard clavulanic acid
products not only endanger public health but also undermine the trust in
legitimate pharmaceutical manufacturers. This issue is especially prevalent in
regions with weaker regulatory oversight and poor supply chain monitoring,
where counterfeit drugs can easily enter the market. For pharmaceutical
companies involved in the production and distribution of clavulanic acid, the
prevalence of counterfeit products presents significant risks, including
reputational damage, legal liabilities, and market share loss. Tackling this
challenge requires a multi-pronged approach, including stronger regulatory
enforcement, improved supply chain transparency, and heightened awareness and
vigilance among healthcare providers and consumers.
Antimicrobial Resistance (AMR) Limitations
Although clavulanic acid remains a potent solution
for combating beta-lactamase-producing bacterial strains, the growing issue of
antimicrobial resistance (AMR) presents a significant challenge. As antibiotic
resistance continues to increase globally, bacterial pathogens are developing
new resistance mechanisms that are more difficult to combat. In some cases,
bacteria have developed resistance not only to the active antibiotic but also
to the beta-lactamase inhibitors like clavulanic acid.
This poses a substantial challenge for
pharmaceutical companies in the clavulanic acid series API market. If
resistance continues to rise, there will be a diminishing effect on the
efficacy of clavulanic acid-based antibiotics. This means that new, more powerful
antibiotics or beta-lactamase inhibitors may need to be developed, leading to
increased R&D costs and potentially slowing down the growth of the
clavulanic acid market. In addition, the increasing reliance on combination
therapies featuring clavulanic acid could see diminishing returns if AMR
continues to evolve, necessitating a shift towards new drugs or alternative
treatment strategies.
Key Market Trends
Increased Demand from the Veterinary Sector
An emerging driver for the Global Clavulanic Acid
Series API Market is the increasing demand for clavulanic acid-based
antibiotics in the veterinary sector. Animals, especially livestock such as
poultry, cattle, and pigs, are often treated with antibiotics to prevent
infections and promote growth. The rise in animal infections caused by
bacterial pathogens resistant to conventional antibiotics has spurred the
demand for combination therapies that include clavulanic acid. These
antibiotics are effective in treating a wide variety of bacterial infections in
animals, including respiratory and gastrointestinal infections.
The growing global demand for animal protein,
especially in emerging markets, has led to an increase in livestock farming.
Consequently, veterinary antibiotics that combine clavulanic acid are becoming
more widely used to control bacterial infections in animals. The increasing
regulations and focus on animal welfare also ensure that only effective
antibiotics, such as those containing clavulanic acid, are used in livestock,
driving demand in the veterinary market and thus contributing to the overall
growth of the clavulanic acid API market.
Technological Advancements in API Manufacturing
Technological innovations in the manufacturing of
clavulanic acid have had a profound impact on the Global Clavulanic Acid Series
API Market. Advances in biotechnology, fermentation processes, and chemical
synthesis have enhanced the efficiency and cost-effectiveness of clavulanic
acid production. These advancements have made it possible to meet growing
global demand while maintaining high-quality standards in API manufacturing.
New manufacturing techniques have also allowed for
scalability in production, making it easier for companies to supply clavulanic
acid APIs at a competitive price point. As the cost of production decreases and
manufacturers become more efficient, the price of clavulanic acid-based drugs
can remain affordable, contributing to their adoption in both developed and
developing regions. The ability to produce clavulanic acid APIs in larger
quantities without compromising quality has further expanded the market, ensuring
that these critical medicines are available to more people around the world.
Segmental Insights
Application Insights
Based on the Application segment,
Oral medications dominated the global Clavulanic Acid Series API market,
particularly in the form of amoxicillin and potassium clavulanate combinations.
Oral formulations, which are typically in the form of tablets, capsules, or
liquid suspensions, represent a larger portion of the market due to their
convenience, ease of use, and cost-effectiveness compared to injectable
medications. This dominance can be attributed to several key factors that make
oral medications more suitable for both patients and healthcare providers.
One of the main reasons oral medications lead the
market is the ease of administration. Oral formulations are easier for patients
to take, as they do not require the need for injections or healthcare
professionals to administer the medication. This is particularly beneficial in
outpatient settings, where patients prefer non-invasive treatments. The
widespread use of oral antibiotics, including those that contain the clavulanic
acid combination, is common for a variety of bacterial infections, such as respiratory
tract infections, urinary tract infections, and sinusitis. The convenience of
oral administration enables patients to take their medication at home, without
the need for frequent visits to clinics or hospitals.
In addition, oral medications are generally more
cost-effective than injectable alternatives. Injectable drugs often require
more complex production processes, stricter storage requirements (such as
refrigeration), and can lead to higher transportation costs. Oral medications,
on the other hand, can be produced more efficiently and have a longer shelf
life, making them more affordable and easier to distribute, especially in
developing countries where healthcare costs are a significant concern. This
price advantage has helped oral medications maintain a dominant market share in
the global clavulanic acid API market, where affordability plays a key role in
prescribing practices, particularly in primary care settings.
Download Free Sample Report
Regional Insights
The Asia Pacific region dominated the
global Clavulanic Acid Series API market, driven by several key factors such as
high demand for antibiotics, increasing healthcare infrastructure, and
expanding pharmaceutical manufacturing capabilities. Asia Pacific's growing
market share in the clavulanic acid API sector can be attributed to the rapid
economic growth, particularly in countries like China, India, and Japan, where
the demand for antibiotics and medicines continues to rise due to population
growth and the increasing prevalence of infectious diseases.
One of the main drivers behind the dominance of
Asia Pacific in the Clavulanic Acid Series API market is the large
pharmaceutical manufacturing industry in the region. India, known as the
"pharmacy of the world," is a significant producer of generic drugs,
including those containing clavulanic acid. The country benefits from a strong
manufacturing base, low production costs, and established regulatory pathways
that make it a competitive player in the global API market. India’s ability to
supply large quantities of generic amoxicillin-clavulanate formulations at
competitive prices has fueled the region’s dominance. The high production
capacity and low labor costs in India make it a preferred manufacturing hub for
Clavulanic Acid APIs, contributing to its widespread availability across
developed and emerging markets.
China, another major player in the region, is also
contributing to the growth of the Clavulanic Acid Series API market. The
country’s government investment in the pharmaceutical sector and growing
healthcare infrastructure have created a conducive environment for the production
and distribution of Clavulanic Acid APIs. China has become one of the largest
producers of APIs globally, with the clavulanic acid series being no exception.
The Chinese government has also implemented various policies to foster the
development of the pharmaceutical industry, including subsidies, incentives,
and the establishment of specialized zones for pharmaceutical manufacturing.
This has enabled China to meet both domestic and global demand for clavulanic
acid APIs.
Recent Developments
- In April 2024, MeCure Industries obtained approval
from the National Agency for Food & Drug Administration and Control
(NAFDAC) in Nigeria to produce Amoxyclav 625 mg, the first locally manufactured
alternative to Amoxicillin-Clavulanic acid tablets.
- In October 2023, researchers from the Ocean
University of China investigated the effects of a combination of aztreonam and
clavulanate against Escherichia coli carrying New Delhi metallo-β-lactamase
(NDM). The study revealed that the combination was more effective in inhibiting
cell wall synthesis compared to aztreonam alone.
- In March 2024, the Central Drug Standard Control
Organization (CDSCO) granted approval to GSK to update the prescribing
information for its fixed-dose combination of Amoxicillin Trihydrate 759.04 mg
(equivalent to Amoxicillin free acid 652.78 mg) and Potassium Clavulanate 61.48
mg (equivalent to Clavulanic acid 50.41 mg) per 5 ml powder, which is to be
reconstituted into a suspension.
- In September 2024, Kinvan, an Indian pharmaceutical
company, began manufacturing its first clavulanic acid product, Augmentin, to
treat a range of bacterial infections. The company plans to invest in building
a 300-metric-ton capacity plant to produce clavulanic acid by the end of 2024.
Key Market Players
- Apotex Inc.
- Centrient Holding B.V.
- CKD BiO Corp.
- Fidia Farmaceutici S.p.A.
- GlaxoSmithKline Plc
- Hikma Pharmaceuticals Plc
- Sandoz Group AG
- Novopharm Formulations Private
Limited
- Rochem International Inc.
- Senova Technology Co. Ltd.
|
By Type
|
By Application
|
By Region
|
- Potassium
Clavulanate
- Amoxicillin
& Potassium Clavulanate
- Potassium
Clavulanate with Avicel
- Potassium
Clavulanate with Silicon Dioxide
|
- Oral
Medications
- Injectable
Medications
|
- North
America
- Europe
- Asia Pacific
- South
America
- Middle East
& Africa
|
Report Scope:
In this report, the Global Clavulanic Acid Series
API Market has been segmented into the following categories, in addition to the
industry trends which have also been detailed below:
- Clavulanic Acid Series API Market, By Type:
o Potassium Clavulanate
o Amoxicillin & Potassium
Clavulanate
o Potassium Clavulanate with
Avicel
o Potassium Clavulanate with
Silicon Dioxide
- Clavulanic Acid Series API Market, By Application:
o Oral Medications
o Injectable Medications
- Clavulanic Acid Series API Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Clavulanic
Acid Series API Market.
Available Customizations:
Global Clavulanic Acid Series API market report
with the given market data, TechSci Research offers customizations according to
a company's specific needs. The following customization options are available
for the report:
Company Information
- Detailed analysis and profiling of additional market
players (up to five).
Global Clavulanic Acid Series API Market is an
upcoming report to be released soon. If you wish an early delivery of this
report or want to confirm the date of release, please contact us at [email protected]